pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

164 catalysts · 40 phase 2 completion · 26 phase 1 completion · 22 phase 1 2 completion · 18 phase 2 initiation · 13 phase 1 2 initiation · 13 phase 1 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: copd×TA: oncology×TA: ophthalmology×clear all
type
  • phase 2 completion40
  • phase 1 completion26
  • phase 1 2 completion22
  • phase 2 initiation18
  • phase 1 2 initiation13
  • phase 1 initiation13
phase 0 trial completion5
  • filing5
  • phase 3 completion4
  • phase 3 initiation4
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 30, 2026phase 1 initiation84d agoQilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)QLS-5212

    Therapy area: Oncology. Indication: Solid Tumor

    full page →QLS-5212 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoVanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)nivolumab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Oral Cavity (Mouth) Cancer, Squamous Cell Carcinoma

    full page →nivolumab →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoGan & Lee Pharmaceuticals Co Ltd — GLR-2037 (Phase I Trial Initiation)GLR-2037

    Therapy area: Oncology. Indication: Prostate Cancer

    full page →GLR-2037 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoAvance Clinical Pty Ltd — ZE-740282 (Phase I Trial Initiation)ZE-740282

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myeloproliferative Disorders, Polycythemia Vera

    full page →ZE-740282 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoByterna Therapeutics Ltd — BR-101 (Phase I Trial Initiation)BR-101

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →BR-101 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoBristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)navlimetostat

    Therapy area: Oncology. Indication: Biliary Tumor, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

    full page →navlimetostat →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoShanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)HLX-3901

    Therapy area: Oncology. Indication: Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →HLX-3901 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoCentre Hospitalier Universitaire de Nice — Leucogenase (Phase I Trial Initiation)Leucogenase

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

    full page →Leucogenase →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoKexing Biopharm Co Ltd — GB-18 (Phase I Trial Initiation)GB-18

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cachexia, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor, Unspecified Cancer

    full page →GB-18 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoBeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)BGC-0979

    Therapy area: Oncology. Indication: Solid Tumor

    full page →BGC-0979 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoAbbVie Inc — blinatumomab (Phase I/II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

    full page →blinatumomab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoBellicum Pharmaceuticals Inc — acetaminophen (Phase I/II Trial Completion)acetaminophen ER

    Therapy area: Oncology. Indication: Breast Cancer, Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoIRCCS Foundation National Cancer Institute — bevacizumab (Phase I/II Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Metastatic Colorectal Cancer

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoZhongshan Hospital — iNKT Cell Immunotherapy (Phase I/II Trial Completion)iNKT Cell Immunotherapy

    Therapy area: Oncology. Indication: Bladder Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

    full page →iNKT Cell Immunotherapy →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoAmsterdam UMC — tremelimumab (Phase I/II Trial Completion)tremelimumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →tremelimumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoInstitute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

    full page →cyclophosphamide →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoZhejiang Doer Biologics Corp — DR-30206 (Phase I/II Trial Completion)DR-30206

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Cancer, Gastrointestinal Tumor, Metastatic Colorectal Cancer

    full page →DR-30206 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

    Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

    full page →verteporfin →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoLepu Biopharma Co Ltd — pucotenlimab (Phase I/II Trial Completion)pucotenlimab

    Therapy area: Oncology. Indication: Pancreatic Cancer

    full page →pucotenlimab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoJiangsu Hengrui Pharmaceuticals Co Ltd — adebrelimab (Phase I/II Trial Completion)adebrelimab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →adebrelimab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoMultitude therapeutics Inc — AMT-253 (Phase I/II Trial Completion)AMT-253

    Therapy area: Non Malignant Disorders, Oncology. Indication: Acral Lentiginous Melanoma, Cervical Cancer, Endometrial Cancer, Gynecological Cancer, Leiomyosarcoma, Melanoma, Metastatic Melanoma, Solid Tumor, Uterine Leiomyoma (Uterine Fibroids)

    full page →AMT-253 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoBayer AG — avelumab (Phase I/II Trial Completion)avelumab

    Therapy area: Oncology. Indication: Bone Metastasis, Malignant Neoplasms, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer

    full page →avelumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoAbbVie Inc — venetoclax (Phase I/II Trial Completion)venetoclax

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Leukemia, Leukemia, T-Cell Leukemia

    full page →venetoclax →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoAstraZeneca Plc — Calquence (Phase I/II Trial Completion)CALQUENCE

    Therapy area: Oncology. Indication: CNS Lymphoma, Diffuse Large B-Cell Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma

    full page →CALQUENCE →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoHenan Cancer Hospital — methotrexate (Phase I/II Trial Completion)Maxtrex

    Therapy area: Oncology. Indication: Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer

    full page →Maxtrex →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoArvinas Inc — samuraciclib (Phase I/II Trial Completion)samuraciclib

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →samuraciclib →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoChiba Cancer Center — nivolumab (Phase I/II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma), Basaloid Squamous Cell Carcinoma, Esophageal Cancer, Squamous Cell Carcinoma

    full page →nivolumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoNational Cheng-Kung University Hospital — cisplatin (Phase I/II Trial Completion)cisplatin

    Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

    full page →cisplatin →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

    Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

    full page →MK-8748 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

    Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

    full page →M-701 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoNational Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)PEP-CMV

    Therapy area: Oncology. Indication: Ependymoma, Glioma, High-Grade Glioma, Medulloblastoma

    full page →PEP-CMV →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoSichuan Kelun Pharmaceutical Co Ltd — SKB-103 (Phase I/II Trial Initiation)SKB-103

    Therapy area: Oncology. Indication: Solid Tumor

    full page →SKB-103 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoRemeGen Co Ltd — RC-288 (Phase I/II Trial Initiation)RC-288

    Therapy area: Oncology. Indication: Melanoma, Non-Small Cell Lung Cancer, Prostate Cancer, Small-Cell Lung Cancer, Solid Tumor

    full page →RC-288 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoFennec Pharmaceuticals Inc — sodium thiosulfate (Phase I/II Trial Initiation)sodium thiosulfate

    Therapy area: Ear Nose Throat Disorders, Oncology. Indication: Esophageal Cancer, Head And Neck Cancer, Hearing Disorders, Lung Cancer, Malignant Pleural Mesothelioma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor)

    full page →sodium thiosulfate →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoDartsbio Pharmaceutical (Guangdong) Co Ltd — DS-010 (Phase I/II Trial Initiation)DS-010

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Cachexia, Cancer Anorexia-Cachexia Syndrome, Solid Tumor

    full page →DS-010 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoInstitute of Hematology & Blood Diseases Hospital — azacitidine (Phase I/II Trial Initiation)Onureg

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)

    full page →Onureg →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoBeijing Bethune Charitable Foundation — bevacizumab (Phase I/II Trial Initiation)bevacizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoBeijing Eastern Biotech Co Ltd — JY-016 (Phase I/II Trial Initiation)JY-016

    Therapy area: Oncology. Indication: Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Recurrent Head And Neck Squamous Cell Carcinoma, Solid Tumor

    full page →JY-016 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation84d agoCompass Therapeutics Inc — CTX-471 (Phase I/II Trial Initiation)CTX-471

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Glioma, Recurrent Glioblastoma Multiforme (GBM)

    full page →CTX-471 →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoGandhi Medical College & Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Oncology. Indication: Malignant Neoplasms

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoQilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)iruplinalkib

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →iruplinalkib →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoIntas Pharmaceuticals Ltd — olaparib (Phase II Trial Completion)olaparib

    Therapy area: Oncology. Indication: Breast Cancer, Castration-Resistant Prostate Cancer (CRPC), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peritoneal Cancer, Solid Tumor

    full page →olaparib →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoMerck & Co Inc — pembrolizumab (Phase II Trial Completion)pembrolizumab

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Gliosarcoma

    full page →pembrolizumab →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoAustralasian Gastro-Intestinal Trials Group — valproate sodium (Phase II Trial Completion)VALPROATE SODIUM

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →VALPROATE SODIUM →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoZhejiang University Hospital One — serplulimab (Phase II Trial Completion)serplulimab

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

    full page →serplulimab →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)aumolertinib mesylate

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer

    full page →aumolertinib mesylate →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoSun Yat-Sen University Hospital 5 — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoShanghai Longfine Biotechnology Co Ltd — toripalimab (Phase II Trial Completion)toripalimab

    Therapy area: Oncology. Indication: Triple-Negative Breast Cancer (TNBC)

    full page →toripalimab →source: globaldata
    ← prev
    page 3 of 4
    next →
    $ONC318.69+2.61%
    $ABBV256.69+0.23%
    $ARVN8.2050-0.67%
    $FENC10.29-0.96%
    $ABBV256.69+0.23%
    $AZN169.34+2.93%
    $REGN672.45-0.41%
    $MRK126.26+1.50%
    $COMP11.42-2.73%